Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5,169,697
-
Total 13F shares
-
9,845,770
-
Share change
-
-4,986,013
-
Total reported value
-
$101,108,715
-
Price per share
-
$10.27
-
Number of holders
-
45
-
Value change
-
-$50,175,043
-
Number of buys
-
16
-
Number of sells
-
35
Institutional Holders of CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) as of Q4 2022
As of 31 Dec 2022,
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,845,770 shares.
The largest 10 holders included
Saba Capital Management, L.P., HSBC HOLDINGS PLC, JANUS HENDERSON GROUP PLC, Westchester Capital Management, LLC, Polar Asset Management Partners Inc., Periscope Capital Inc., Beryl Capital Management LLC, HGC Investment Management Inc., First Trust Capital Management L.P., and BERKLEY W R CORP.
This page lists
45
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.